B-condition	0	4	Pain
O	5	13	outcomes
O	14	16	in
O	17	25	patients
O	26	30	with
O	31	39	advanced
O	40	46	breast
O	47	53	cancer
O	54	57	and
O	58	62	bone
O	63	73	metastases
O	73	74	:
O	75	82	results
O	83	87	from
O	88	89	a
O	90	100	randomized
O	100	101	,
O	102	108	double
O	108	109	-
O	109	114	blind
O	115	120	study
O	121	123	of
O	124	133	denosumab
O	134	137	and
O	138	148	zoledronic
O	149	153	acid
O	153	154	.

O	155	157	In
O	158	162	this
O	163	168	study
O	168	169	,
O	170	173	the
O	174	181	authors
O	182	191	evaluated
O	192	195	the
O	196	202	effect
O	203	205	of
B-intervention	206	215	denosumab
O	216	222	versus
B-control	223	233	zoledronic
I-control	234	238	acid
I-control	239	240	(
I-control	240	242	ZA
I-control	242	243	)
O	244	246	on
O	247	251	pain
O	252	254	in
B-eligibility	255	263	patients
I-eligibility	264	268	with
I-eligibility	269	277	advanced
I-eligibility	278	284	breast
I-eligibility	285	291	cancer
I-eligibility	292	295	and
I-eligibility	296	300	bone
I-eligibility	301	311	metastases
O	311	312	.

O	313	316	The
O	317	327	prevention
O	328	330	of
O	331	335	pain
O	335	336	,
O	337	346	reduction
O	347	349	in
O	350	354	pain
O	355	367	interference
O	368	372	with
O	373	378	daily
O	379	383	life
O	384	394	activities
O	394	395	,
O	396	399	and
O	400	403	the
O	404	414	proportion
O	415	417	of
O	418	426	patients
O	427	436	requiring
O	437	443	strong
O	444	450	opioid
O	451	461	analgesics
O	462	466	were
O	467	475	assessed
O	476	478	in
O	479	480	a
O	481	491	randomized
O	491	492	,
O	493	499	double
O	499	500	-
O	500	505	blind
O	505	506	,
O	507	513	double
O	513	514	-
O	514	519	dummy
O	520	525	phase
O	526	527	3
O	528	533	study
O	534	543	comparing
O	544	553	denosumab
O	554	558	with
O	559	561	ZA
O	562	565	for
O	566	576	preventing
O	577	585	skeletal
O	585	586	-
O	586	593	related
O	594	600	events
O	601	603	in
B-total-participants	604	608	2046
O	609	617	patients
O	618	621	who
O	622	625	had
O	626	632	breast
O	633	639	cancer
O	640	643	and
O	644	648	bone
O	649	659	metastases
O	659	660	.

O	661	669	Patients
O	670	679	completed
O	680	683	the
O	684	689	Brief
O	690	694	Pain
O	695	704	Inventory
O	704	705	-
O	705	710	Short
O	711	715	Form
O	716	718	at
O	719	727	baseline
O	728	731	and
O	732	739	monthly
O	740	750	thereafter
O	750	751	.

O	752	757	Fewer
O	758	766	patients
O	767	770	who
O	771	779	received
O	780	789	denosumab
O	790	798	reported
O	799	800	a
O	801	811	clinically
O	812	822	meaningful
O	823	832	worsening
O	833	835	of
B-outcome	836	840	pain
I-outcome	841	849	severity
O	850	851	(
O	851	852	â‰¥
O	852	853	2
O	853	854	-
O	854	859	point
O	860	868	increase
O	868	869	)
O	870	874	from
O	875	883	baseline
O	884	892	compared
O	893	897	with
O	898	906	patients
O	907	910	who
O	911	919	received
O	920	922	ZA
O	922	923	,
O	924	927	and
O	928	929	a
O	930	935	trend
O	936	939	was
O	940	948	observed
O	949	955	toward
O	956	963	delayed
B-outcome	964	968	time
I-outcome	969	971	to
I-outcome	972	976	pain
I-outcome	977	986	worsening
O	987	991	with
O	992	1001	denosumab
O	1002	1008	versus
O	1009	1011	ZA
O	1012	1013	(
O	1013	1022	denosumab
O	1022	1023	,
B-iv-cont-mean	1024	1025	8
I-iv-cont-mean	1025	1026	.
I-iv-cont-mean	1026	1027	5
I-iv-cont-mean	1028	1034	months
O	1034	1035	;
O	1036	1038	ZA
O	1038	1039	,
B-cv-cont-mean	1040	1041	7
I-cv-cont-mean	1041	1042	.
I-cv-cont-mean	1042	1043	4
I-cv-cont-mean	1044	1050	months
O	1050	1051	;
O	1052	1053	P
O	1054	1055	=
O	1056	1057	.
O	1057	1059	08
O	1059	1060	)
O	1060	1061	.

O	1062	1064	In
O	1065	1073	patients
O	1074	1077	who
O	1078	1081	had
O	1082	1084	no
O	1084	1085	/
O	1085	1089	mild
O	1090	1094	pain
O	1095	1097	at
O	1098	1106	baseline
O	1106	1107	,
O	1108	1109	a
O	1110	1111	4
O	1111	1112	-
O	1112	1117	month
O	1118	1123	delay
O	1124	1126	in
B-outcome	1127	1138	progression
I-outcome	1139	1141	to
I-outcome	1142	1150	moderate
I-outcome	1150	1151	/
I-outcome	1151	1157	severe
I-outcome	1158	1162	pain
O	1163	1166	was
O	1167	1175	observed
O	1176	1180	with
O	1181	1190	denosumab
O	1191	1199	compared
O	1200	1204	with
O	1205	1207	ZA
O	1208	1209	(
B-iv-cont-mean	1209	1210	9
I-iv-cont-mean	1210	1211	.
I-iv-cont-mean	1211	1212	7
I-iv-cont-mean	1213	1219	months
O	1220	1222	vs
B-cv-cont-mean	1223	1224	5
I-cv-cont-mean	1224	1225	.
I-cv-cont-mean	1225	1226	8
I-cv-cont-mean	1227	1233	months
O	1233	1234	;
O	1235	1236	P
O	1237	1238	=
O	1239	1240	.
O	1240	1243	002
O	1243	1244	)
O	1244	1245	.

O	1246	1255	Denosumab
O	1256	1263	delayed
O	1264	1267	the
B-outcome	1268	1272	time
I-outcome	1273	1275	to
I-outcome	1276	1285	increased
I-outcome	1286	1290	pain
I-outcome	1291	1303	interference
O	1304	1306	by
O	1307	1320	approximately
O	1321	1322	1
O	1323	1328	month
O	1329	1337	compared
O	1338	1342	with
O	1343	1345	ZA
O	1346	1347	(
O	1347	1356	denosumab
O	1356	1357	,
B-iv-cont-mean	1358	1360	16
I-iv-cont-mean	1360	1361	.
I-iv-cont-mean	1361	1362	0
I-iv-cont-mean	1363	1369	months
O	1369	1370	;
O	1371	1373	ZA
O	1373	1374	,
B-cv-cont-mean	1375	1377	14
I-cv-cont-mean	1377	1378	.
I-cv-cont-mean	1378	1379	9
I-cv-cont-mean	1380	1386	months
O	1386	1387	;
O	1388	1389	P
O	1390	1391	=
O	1392	1393	.
O	1393	1395	09
O	1395	1396	)
O	1396	1397	.

O	1398	1401	The
B-outcome	1402	1406	time
I-outcome	1407	1409	to
I-outcome	1410	1414	pain
I-outcome	1415	1426	improvement
O	1427	1428	(
O	1428	1429	P
O	1430	1431	=
O	1432	1433	.
O	1433	1435	72
O	1435	1436	)
O	1437	1440	and
O	1441	1444	the
B-outcome	1445	1449	time
I-outcome	1450	1452	to
I-outcome	1453	1462	decreased
I-outcome	1463	1467	pain
I-outcome	1468	1480	interference
O	1481	1482	(
O	1482	1483	P
O	1484	1485	=
O	1486	1487	.
O	1487	1489	92
O	1489	1490	)
O	1491	1495	were
O	1496	1503	similar
O	1504	1511	between
O	1512	1515	the
O	1516	1522	groups
O	1522	1523	.

O	1524	1529	Fewer
O	1530	1539	denosumab
O	1539	1540	-
O	1540	1547	treated
O	1548	1556	patients
O	1557	1565	reported
O	1566	1575	increased
B-outcome	1576	1585	analgesic
I-outcome	1586	1589	use
O	1590	1594	from
O	1595	1597	no
O	1597	1598	/
O	1598	1601	low
O	1602	1605	use
O	1606	1608	at
O	1609	1617	baseline
O	1618	1620	to
O	1621	1627	strong
O	1628	1634	opioid
O	1635	1638	use
O	1638	1639	.

O	1640	1649	Denosumab
O	1650	1662	demonstrated
O	1663	1671	improved
O	1672	1676	pain
O	1677	1687	prevention
O	1688	1691	and
O	1692	1702	comparable
O	1703	1707	pain
O	1708	1718	palliation
O	1719	1727	compared
O	1728	1732	with
O	1733	1735	ZA
O	1735	1736	.

O	1737	1739	In
O	1740	1748	addition
O	1748	1749	,
O	1750	1755	fewer
O	1756	1765	denosumab
O	1765	1766	-
O	1766	1773	treated
O	1774	1782	patients
O	1783	1790	shifted
O	1791	1793	to
O	1794	1800	strong
O	1801	1807	opioid
O	1808	1817	analgesic
O	1818	1821	use
O	1821	1822	.
